Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


NIAID launches first Phase II trial of a ’global’ HIV/AIDS vaccine


A novel vaccine targeted to multiple HIV subtypes found worldwide has moved into the second phase of clinical testing, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today. The study investigators plan to enroll a total of 480 participants at sites in Africa, North America, South America and the Caribbean to test the safety and immune response to the vaccine.

The experimental vaccine was developed by scientists at NIAID’s Dale and Betty Bumpers Vaccine Research Center (VRC) and is being studied in the HIV Vaccine Trials Network (HVTN), a clinical research collaboration funded by NIAID’s Division of AIDS (DAIDS).

"This trial marks an important step in the advancement toward an AIDS vaccine. The rapid development of this candidate vaccine--less than five years since the launch of the VRC--underscores our commitment to hasten the day when we have an effective AIDS vaccine," says NIAID Director Anthony S. Fauci, M.D.

The unique vaccine combines synthetically modified elements of four HIV genes found in subtypes A, B and C of the virus--the subtypes commonly found in Africa, the Americas, Europe and parts of Asia. These subtypes represent about 85 percent of HIV infections worldwide.

"This is the first Phase II study of a vaccine candidate that is broadly relevant to the global AIDS pandemic because it combines components of HIV strains found throughout the world," says VRC Director Gary Nabel, M.D., Ph.D. "We look forward to working with our partners in the United States and abroad as we take this vaccine into the next phase of clinical evaluation."

The trial, known as HVTN 204, is being coordinated with two other planned clinical studies, an unprecedented collaboration among researchers in three clinical trial networks and NIAID. The International AIDS Vaccine Initiative plans to conduct a Phase I study of the VRC vaccine at sites in Kenya and Rwanda, and the U.S. Military HIV Research Program plans Phase I and II studies at sites in Uganda, Kenya and Tanzania; the studies are contingent on the appropriate regulatory and ethical approvals being granted in these countries.

About the Vaccine

The three harmonized trials will be testing a "prime-boost" strategy composed of two vaccine components given at different times. Both contain synthetic versions of four HIV genes: gag, pol, nef and env. The gag, pol and nef genes come from HIV subtype B, the primary virus found in Europe and North America. Env, the fourth gene, codes for an HIV coat protein that allows the virus to recognize and attach to human cells. The vaccine incorporates modified env genes from subtypes A and C, most common in Africa and parts of Asia, as well as subtype B.

The two vaccine components differ in how the genes are packaged. One contains only the naked gene fragments, which cannot reconstitute into an infectious virus. The other uses a weakened type of respiratory virus known as adenovirus as a vector to shuttle the non-infectious gene fragments into the body.

Adenoviruses cause upper respiratory tract illness, such as the common cold. However, because the vaccine contains only HIV gene fragments housed in an adenovirus that cannot replicate, study participants cannot become infected with HIV or get a respiratory infection from the vaccine.

"The use of adenovirus vectors appears to be the most promising advance in recent years in the search for an HIV vaccine," says Peggy Johnston, Ph.D., director of the Vaccine and Prevention Research Program in DAIDS, NIAID. Lawrence Corey, M.D., principal investigator of the HVTN, adds, "We are excited to work with the VRC on this new vaccine candidate. This prime-boost approach incorporating adenovirus vector seems to generate the type and quantity of immune responses we feel will be necessary to impact an infection like HIV. This study will define more completely the levels of immunity this novel approach will achieve in a broad range of people."

The DNA components of the vaccine were manufactured by the San Diego-based Vical, Inc. The adenovirus vector was developed by VRC in collaboration with GenVec Inc., of Gaithersburg, Md., which also manufactured the adenovirus vector vaccine.

HVTN 204 Study Details

The HVTN 204 Phase II study will test the safety and ability of the vaccine to generate an immune response in 480 healthy, HIV-negative adults ages 18 to 50. The researchers plan to recruit volunteers from populations particularly hard-hit by AIDS, including African Americans and other ethnic minorities.

The study is being led by Michael Keefer, M.D., of the University of Rochester, NY, and Gavin Churchyard, M.B.B.Ch., F.C.P., M.Med., Ph.D., of Aurum Health Research Ltd. in South Africa.

The trial opened at the University of Alabama at Birmingham and is designed to include 13 HVTN sites, provided that regulatory and ethical approval is granted at each site:

  • North America--Baltimore, MD; Boston, MA; Providence, RI; Birmingham, AL; Nashville, TN; and Rochester, NY
  • South America--Rio de Janeiro and São Paulo, Brazil
  • Caribbean--Port-au-Prince, Haiti; Kingston, Jamaica
  • Africa--Gaborone, Botswana; and Cape Town, Soweto, and KOSH (Klerksdorp, Orkney, Stilfontein, and Hartbeesfontein), South Africa

Half of the 480 trial participants will be enrolled in the Americas (Haiti, Jamaica, Brazil and the United States) and half in southern Africa (Botswana and South Africa). The geographic diversity of participants allows the researchers to evaluate whether the immune responses generated to the vaccine vary according to the amount of prior exposure to adenovirus, as measured by pre-existing levels of adenovirus antibodies. Africans, for example, generally have had greater exposure to adenovirus than people living in North America.

The participants, divided into two groups, will receive four injections spread out over a period of six months. One group will receive three injections of the naked DNA component followed by a booster injection of the adenoviral vector component. The second group will receive four injections of a placebo vaccine consisting of sterile saltwater. Because the study is "double blind," neither the participants nor the researchers will know whether a volunteer is receiving the study vaccine or the placebo until the end of the trial.

NIAID News Office | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Inflammation Triggers Unsustainable Immune Response to Chronic Viral Infection
24.10.2016 | Universität Basel

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Ice shelf vibrations cause unusual waves in Antarctic atmosphere

25.10.2016 | Earth Sciences

Fluorescent holography: Upending the world of biological imaging

25.10.2016 | Power and Electrical Engineering

Etching Microstructures with Lasers

25.10.2016 | Process Engineering

More VideoLinks >>>